Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
about
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
description
2020 nî lūn-bûn
@nan
2020年の論文
@ja
2020年学术文章
@wuu
2020年学术文章
@zh
2020年学术文章
@zh-cn
2020年学术文章
@zh-hans
2020年学术文章
@zh-my
2020年学术文章
@zh-sg
2020年學術文章
@yue
2020年學術文章
@zh-hant
name
Safety and immune responses af ...... subtype C gp120/MF59 vaccines
@en
type
label
Safety and immune responses af ...... subtype C gp120/MF59 vaccines
@en
prefLabel
Safety and immune responses af ...... subtype C gp120/MF59 vaccines
@en
P2093
P50
P1433
P1476
Safety and immune responses af ...... subtype C gp120/MF59 vaccines
@en
P2093
Brodie Daniels
Carlos A DiazGranados
Carter Bentley
Chenchen Yu
James G Kublin
Kevin Saunders
Linda-Gail Bekker
Michael N Pensiero
Mookho Malahleha
Nicole L Yates
P304
P356
10.1371/JOURNAL.PMED.1003038
P50
P577
2020-02-24T00:00:00Z